LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

LLY

998.66

+1.35%↑

JNJ

228.31

+2.17%↑

ABBV

206.78

+0.54%↑

UNH

397.03

+3.34%↑

AZN

185.68

+0.93%↑

Home・Akcijų sąrašas・VolitionRX Ltd

VolitionRX Ltd

Atidarymo kaina

2.1 -4.55

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.1

Max

2.36

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+1624.14% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-14

VolitionRX Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-12 22:50; UTC

Uždarbis

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026-05-12 22:49; UTC

Uždarbis

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026-05-12 22:32; UTC

Uždarbis

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026-05-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026-05-12 22:57; UTC

Rinkos pokalbiai

Uždarbis

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026-05-12 22:26; UTC

Uždarbis

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure Interim Dividend A$0.50/Security

2026-05-12 22:24; UTC

Uždarbis

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026-05-12 22:19; UTC

Uždarbis

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026-05-12 22:13; UTC

Uždarbis

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026-05-12 22:11; UTC

Uždarbis

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026-05-12 22:11; UTC

Uždarbis

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026-05-12 22:10; UTC

Uždarbis

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026-05-12 22:08; UTC

Uždarbis

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026-05-12 22:07; UTC

Uždarbis

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026-05-12 22:05; UTC

Uždarbis

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Akcijų palyginimas

Kainos pokytis

VolitionRX Ltd Prognozė

Kainos tikslas

By TipRanks

1624.14% į viršų

12 mėnesių prognozė

Vidutinis 40 USD 1624.14%

Aukščiausias 60 USD

Žemiausias 20 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines VolitionRX Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių VolitionRX Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.